Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02218489 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
A Phase 2 study, sponsored by Kala Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 206
- Enrollment target
NCT02218489 is a Phase 2 study that has completed, run by Kala Pharmaceuticals. The registered enrollment target is 206 participants.
The verdict
NCT02218489, a Phase 2 study, has completed, sponsored by Kala Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 206 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to vehicle (placebo) in subjects with signs and symptoms of inflammatory meibomian gland disease.
Interventions
- DRUG Vehicle
- DRUG KPI-121
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2014-07 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02218489
The ClinicalTrials.gov registry entry for NCT02218489 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kala Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT02218489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02218489 about?
NCT02218489 is a clinical study titled "Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease". The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to vehicle (placebo) in subjects with signs and symptoms of inflammatory meibomian gland disease.
What is the current status of trial NCT02218489?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 206 participants. The study started on 2014-07. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02218489?
The interventions under investigation include: Vehicle (DRUG), KPI-121 (DRUG).
Who is sponsoring clinical trial NCT02218489?
This trial is sponsored by Kala Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.